NEW TECHNOLOGIES TO DRIVE DRUG DISCOVERY AND DEVELOPMENT

NEW TECHNOLOGIES TO DRIVE DRUG DISCOVERY AND DEVELOPMENT INTRODUCING NEXT GENERATION DECISION SUPPORT & INFORMATICS SOLUTIONS FOR LIFE SCIENCES COMPANIES

TURNING INFORMATION INTO INSIGHT IS DIFFICULT

• Content is hidden behind product

interfaces

• Different content sources are difficult to

combine and require time to curate

• Analyses tend to be either “one size fits all”

or so specific that they can’t be re-used

• The presentation of data often depends on

the skills and personal preferences of a

presenter

IDEALLY, INFORMATION IS…

• Relevant and timely

• Able to be combined with other data and/or internal

business logic

• Presented so it is natural for users to consume and

interact with it

• Possible to interrogate and evaluate

• Easily updated

CLINICAL DECISION SUPPORT NEW TECHNOLOGIES IN ACTION

CLINICAL DECISION SUPPORT What challenges do the

Decision Support applications

address?

• Drug development teams need information as and when the question arises

• Information needs to be presented at a level of abstraction to make it actionable, but

with the supporting data underneath

• Different teams present in different ways making it difficult to make apples-to-apples

comparisons

How the Applications Address

these challenges

• The Applications enable customers to select an area of interest, get a visual

representation of the data, tailor it using filters, and drop it into PowerPoint for their

presentation without having to ask for data or use a separate analysis package

• Pre-loaded data ensures that that users do not miss important new information between

reporting intervals

How it’s delivered

• Configurable Spotfire® dashboards that can accessed over the Internet via a web player

or hosted locally by a client

• The dashboards are optimized for mobile tablet devices

• Dashboards can be configured so to include filters on several different criteria

depending upon requirements

Where does the information

come from • The dashboards are powered by pipeline and clinical information from Cortellis, human-

curated from patents, journals, meetings, web pages, press-releases, trial-registries, etc.

Benefits

• Eliminate hours of searching and curating data and spend more time analyzing

information and making decisions

• Drive uniform appearance of results within presentations across products portfolios

• Provide transparency around the sources of the information

• Easily discern changes to data between presentations

THE FIRST 5 CLINICAL DECISION SUPPORT APPLICATIONS – OPTIMISED FOR THE iPAD

TRIAL DURATION VIEWER

What questions does the

viewer answer?

• What is the timeline for drugs in clinical trials, by class of drug, indication,

company?

• What are the likely durations of trials in an indication by phase?

How is data selected? • Users can select data for a drug, indication or trial sponsor

What visualisations are

available?

• A GANTT-like timeline view including projected end dates when no sponsor

estimate is available

• A box-plot of trial durations for completed trials

What drill-downs are

available?

• All drug records have links to the records on Cortellis

• Summary information on the trial includes biomarkers, patient numbers, title &

references

Benefits • View the competitive landscape around a trial in progress

• Gain insight into the likely durations of clinical trials

TRIAL DURATION VIEWER – SELECTING WHAT TO VIEW

Search/br

owse by

indication,

sponsor

or drug

Link to Cortellis

Select a

visualization

Select a term

TRIAL DURATION VIEWER – THE TIMELINE VIEW

Navigation

controls

Details of

selected

trial(s)

Filtered to

P2-3 trials,

not

terminated,

sponsored

by drug

owner

TRIAL DURATION VIEWER – THE DURATIONS VIEW

outliers

Details of

selected

trial(s)

Variance in

trial

duration by

phase

Filters

allow, e.g.

looking at

impact of

patient

numbers

PORTFOLIO VIEWER


viewer answer?

• What is the competitive position of a drug in development?

How is data selected? • Users can select data for an action, company or indication


available?

• A bubble chart landscape visualization that shows the “crowdedness” of the

competitive space

• A funnel visualization that shows the progress of drugs through the pipeline

• A visualization of the drug development history for one or more drugs


available? • All drug records have links to the records on Cortellis

• Status of the drug in all indications in all regulatory authorities

Benefits • View the competitive landscape for a drug

• Highlight recent changes in the competitive position

PORTFOLIO VIEWER – THE FUNNEL VIEW

Choose

drug labels

& colours

Details of

selected

drug(s)

Link to

Cortellis

Navigation

controls

Filtered to

exclude

withrawn,

suspended,

discontinued,

no

development

reported

drugs

PORTFOLIO VIEWER – THE LANDSCAPE VIEWER

Details of

selected

drug(s)

Filtered to

active drugs

that have

changed

status in the

past year

PORTFOLIO VIEWER – THE DEVELOPMENT HISTORY CHART VIEW

Filtered to US

(FDA) events

Columns

show

status by

indication

& company

by country

DRUG PROGRAM VIEWER


viewer answer?

• What is the progression of trials in different indication, by different sponsors for a

given drug?

How is data selected? • Users can select individual drugs to view


available? • A left-to-right or top-to-bottom view of the trial


available?


• Manually curated details of outcomes and adverse events for completed trials,

trial phase, status, sponsor, indication, etc. of all trials

Benefits • Gain an insight into the thoughts of the team developing the drug, successes or

failures in different (sub)indications, etc.

DRUG PROGRAM VIEWER – LEFT-TO-RIGHT (PERT) VIEW

Choose

labels &

colours

Filtered to

NSLC

Details of

selected

trial(s)

DRUG PROGRAM VIEWER– DETAILS VIEW

DISEASE AREA VIEWER


viewer answer?

• What segments in an indication are competitors going after?

How is data selected? • Users can select data for an indication from the Cortellis indication hierarchy


available?

• A Pie-chart view of trials by phase showing unsegmented vs molecular-

segmented trials

• A bar chart of trials showing which segments have been looked at in trials


available?

• The statements made in the trial protocol that suggest that this trial is in a

segmented population

Benefits • View the actual competition for a targeted therapy as opposed to all the drugs in

this indication

• See the level of confidence in targeted subpopulations in an indication

DISEASE AREA VIEWER – SEGMENTS BY PHASE

Segments

by trials or

drugs

Evidence

for

segmentati

on

DRUG SAFETY VIEWER


viewer answer?

• What is the adverse event profile of a competitor drug disclosed in clinical trials?

How is data selected? • Users can select a set of drugs to compare by name or mechanism of action


available? • A Heat Map showing the adverse events reported in trials by number of trials or

number of patients affected


available?


• Status, Phase, Indications, title and a summary of the adverse events reported in

each trial

Benefits • Compare a number of drugs to aid in differentiating a drug from its competitors by

safety profile

DRUG SAFETY VIEWER – DRUG SELECTION

Search by

name or

action

Pick drugs

of interest

Manage list

of selected

drugs

Navigation

controls

DRUG SAFETY VIEWER – HEAT MAP VIEW

Choose

view

parameters

Details of

selected

trials

WEB SERVICES APIS NEW TECHNOLOGIES IN ACTION

WEB SERVICES APIs

• Industry-Standard way to make structured, “Deep

Web” content available to users

– Works through firewalls

– Many tools available to consume APIs

• Two common protocols, we support both

– REpresentional State Transfer (REST)

– Simple Object Access Protocol (SOAP)

API SUPPORT

• Support site at

http://developercenter.thomsonreuters.com

• Documentation

• Sample Code

• Tips & Tricks

• Support community

http://developercenter.thomsonreuters.com/

INVESTIGATIONAL DRUGS - SEARCH

Autocomplete getDrugResults

getCIMatrix

getTaxonomy

TopLevel

getCompanyResults,

getDealResults

Sample client built in Drupal (PHP, PERL)

INVESTIGATIONAL DRUGS - BROWSE

exportDrugResults getCompanyResults

getDiseaseResults

getDrugResults

getDrugRecord Sample client built in Drupal (PHP, PERL)

INVESTIGATIONAL DRUGS – FULL RECORD

Sample client built in Microsoft

SharePoint Web Parts (C#)

INVESTIGATIONAL DRUGS – CI MATRIX


SilverLight

TARGETS - SEARCH



getTargetResults

getTaxonomy

TopLevel

TARGETS - BROWSE

getTargetRecord



TARGETS - RESULTS

Sample client built in Drupal (PHP, PERL)

getReference

Record

getDrugRecord

getPatentRecord

Mash-up with

PDB API

TARGETS – DRUG RECORDS


SharePoint Web Parts (C#) & ChemAxon’s Marvin

TARGETS - ANALYTICS

Sample client built in C# and Adobe Flash

ONTOLOGIES – TAXONOMY SEARCH/BROWSE

REST Call to browse the root terms: https://lsapi.thomson-

pharma.com/ws/rs/ontologies-v1/taxonomy/condition/root

Get the children of a node:

https://lsapi.thomson-

pharma.com/ws/rs/ontologies-

v1/taxonomy/condition/children/182

Search the entire tree: https://lsapi.thomson-pharma.com/ws/rs/ontologies-

v1/taxonomy/condition/search/arteriopathy?operationType=flat

ONTOLOGIES – SYNONYM RESOLUTION https://lsapi.thomson-pharma.com/ws/rs/ontologies-v1/synonyms/drug/cele

PATENTS – SEARCH & RETRIEVE RESULTS

getPatentResults

SSQL query

language



PATENT – DETAILED RECORD

exportPatentResults



CLINICAL – SEARCH & RETRIEVE RESULTS

getTrialResults

getTrialRecord



CLINICAL – DETAILED TRIAL RECORD

exportTrialResults



IN DEVELOPMENT FOR Q2 2012

• Drug Development v1

– Experimental Pharmacology and PK information from

Integrity

• Ontologies v2

– Autogeneration of TR terms from unstructured text

– Summary descriptions of TR entities

• Analytics v3

– Addition of patents data

• Regulatory v1

– Regulatory Reports, Global Regulatory Comparisons from

IDRAC

API ROADMAP

Q1 Q2 Q3 Q4 2013

Investigational

Drugs

V3 Structure Search,

Integrated

Deals/Drugs/Companies

Targets V3 Structure Search

Ontologies V2 Auto indexing V3 New mappings V4 MetaCore

Analytics V2 Trials V3 Patents

Patents V1 V2 Extended

Drug Design V1 Core Drugs, PK/PD

& Exp. Pharm.

V2 Structure Search

DMPK & Property

Calculation

Clinical V1 Trials V2 Literature, Meetings V3 Biomarkers

Regulatory V1 Regulatory Reports

& Comparisons

Omics V1 Pathways

Omics

Analytics

V1 List processing

News V1 Cortellis News

Generics V1

PARTNERSHIP ECOSYSTEM

“To enable better decision making for our customers by making Thomson

Reuters knowledge available at the point of need.”

Thomson Reuters’ content should be seamlessly integrated into our clients

work flow at the point where it adds most value.

Relevant knowledge should be presented at the pertinent time clearing the way

for our clients to make more informed decisions.

PARTNERSHIP ECOSYSTEM

PIPELINE PILOT COMPONENTS - TARGETS

DRUG TARGET REPORT – SAMPLE PROTOCOL

• Show me all targets associated with both the Activated Toll-like

Receptor 4 Signaling pathway and Amyloidosis and then all

compounds which are inhibitors of those targets

TripleMap

IDBS ELECTRONIC LAB NOTEBOOK

Integrating biology, chemistry and pharmacology data on more than 320,000 compounds

with demonstrated biological activity and almost 140,000 patent family records

IDBS ELECTRONIC LAB NOTEBOOK

INFORSENSE WORKFLOWS

KNIME – COMING SOON!

Extract Facts and

Relationships

Use NLP to

Interpret Meaning

Link back to Cortellis

for more context

Store facts and relationships

in Cortellis Build on existing mark-up

CORTELLIS WITH I2E ENHANCES THE

VALUE OF DATA

SEARCH GENIUS FOR SHAREPOINT™

• SharePoint is the market leading document management system for storing loose document records:

however, it lacks structure searching capability

• E-Notebook is the market leading electronic notebook, capturing a variety of scientific workflows but

often capturing extensive chemical reaction information

• SearchGenius For SharePoint™ provides chemical searching capability for SharePoint and federated

searching across SharePoint, E-Notebook, Thomson Reuters Cortellis and the web

QUESTIONS?

[email protected]

Documents

NEW TECHNOLOGIES TO DRIVE DRUG DISCOVERY AND DEVELOPMENT